The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review
Open accessAbstract
BACKGROUND: The prognosis, specifically the case fatality and duration, of untreated tuberculosis is important as many patients are not correctly diagnosed and therefore receive inadequate or no treatment. Furthermore, duration and case fatality of tuberculosis are key parameters in interpreting epidemiological data. METHODOLOGY AND PRINCIPAL FINDINGS: To estimate the duration and case fatality of untreated pulmonary tuberculosis in HIV negative patients we reviewed studies from the pre-chemotherapy era. Untreated smear-positive tuberculosis among HIV negative individuals has a 10-year case fatality variously reported between 53% and 86%, with a weighted mean of 70%. Ten-year case fatality of culture-positive smear-negative tuberculosis was nowhere reported directly but can be indirectly estimated to be approximately 20%. The duration of tuberculosis from onset to cure or death is approximately 3 years and appears to be similar for smear-positive and smear-negative tuberculosis. CONCLUSIONS: Current models of untreated tuberculosis that assume a total duration of 2 years until self-cure or death underestimate the duration of disease by about one year, but their case fatality estimates of 70% for smear-positive and 20% for culture-positive smear-negative tuberculosis appear to be satisfactory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selection of papers. Flowchart schematically showing inclusion and exclusion of papers. Those marked with a * were excluded either because they were referred to at places in the text that did not discuss duration of tuberculosis, tuberculosis mortality, case fatality, life tables or natural history, or because the title indicated that the paper was not about one of these topics; ** for two of these, data were included to the extent mentioned by Berg [115] (see legend of Table 3).](https://figures.cochat.ai/paper-figures/8114c3bf70fd484d9fe91b2b4854751c/natural-history-of-tuberculosis-duration-and-fatality-of-untreated-pulmonary-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the average duration until cure or death is 3 years for untreated patients with tuberculosis,25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 2×
“a 70% CF, as used by WHO and others in their estimates of the burden of tuberculosis [27], seems a reasonable ballpark figure.”
BackgroundMethodSelf-citationTuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932 · cited 1×
“tuberculosis and progression to tuberculosis disease is influenced by host factors and especially risk of progression depends on the hosts’ immune status, which may be reduced due to concomitant HIV infection, diabetes, and other underlying diseases [27,28].”
BackgroundFluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review
Steingart, K. R., Henry, M., Ng, V., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70578-3 · Cited by 798 · cited 1×
“smear, with low sensitivity for paucibacillary disease, is the only available diagnostic tool [6].”
BackgroundThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“Furthermore, Mycobacterium tuberculosis strains resistant to rifampicin and INH might be less fit than drug susceptible strains and therefore lead to longer duration of disease with less mortality [15].”
BackgroundDye, C. (2005) · JAMA · doi:10.1001/jama.293.22.2767 · Cited by 534 · cited 1×
“course) strategy only offer free treatment to smear-positive cases in view of their disproportionate role in tuberculosis transmission and thus their large public health impact [7].”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 1×
“The prognosis of untreated tuberculosis is difficult to study these days as leaving patients untreated, especially in a study setting, is unethical. As an alternative, one could consider, as an approximation, the prognosis of multi-drug resistant (MDR) tuberculosis treated with first line drugs. However, MDR-tuberculo…”
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483 · cited 4×
“As regards CF, the review of Payne and Bellamy [143] provided no information on the prognosis of HIV positive MDR-tuberculosis patients.”
BackgroundInfluentialTreatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection
Small, P. M., Schecter, G. F., Goodman, P. C., Sande, M. A., Chaisson, R. E., & Hopewell, P. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240503 · Cited by 477 · cited 1×
“tuberculosis, of 16 months [145].”
The White Plague: Tuberculosis, Man and Society
(1954) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1954.tb85837.x · Cited by 388
Recurrence in tuberculosis: relapse or reinfection?
Lambert, M.-L., Hasker, E., Deun, A. V., Roberfroid, D., Boelaert, M., & Van der Stuyft, P. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00607-8 · Cited by 225 · cited 1×
“Moreover, of the two possible end points, cure is hard to measure, as relapses are common [140] and establishing cure in untreated tuberculosis patients requires extensive medical investigations.”
Background
Research works printed but not linked: 25
- JA Rutledge, 1919, The ultimate results in 1654 cases of tuberculosis treated at the modern Woodmen of America sanatorium., Am Rev Tuberc, 2, 755
- E Loewenstein, 1931, Die Zuchtung der Tuberkelbazillen aus dem stroemenden Blute., Zentralbl Bakteriol Parasitenkd Infektionskr Hyg, 1, 127
- KA Jensen, 1932, Reinzuchtung und Typenbestimmung von Tuberkelbazillenstammen., Zentralb Bakteriol Parasitenkd Infektionskr Hyg Abt, 1, 222
- GH Hamel, 1928, Jahresversammlung des Deutschen Zentral-komitees zur Bekämpfung der Tuberkulose. Erster Verhandlungstag. (discussions during annual meeting of the German Tuberculosis Control Committee)., Zeitschr Tuberk, 51, 497
- B Meidell, 1931, Die wahrscheinliche Lebensdauer und die Sterblichkeitsmessung., Skandinavisk aktuarietidskrift, 14, 217
- Anonymous, 1936, The expectation of life of the tuberculous., Tubercle, 17, 171
- F Oldenburg, 1931, Gedanken über das Schicksal offentuberkulöser Eisenbahner auf Grund statistischer Erhebungen., Zeitschr Tuberk, 61, 334
- S Phillips, 1964, Relapse in treated cases of pulmonary tuberculosis. II. Six-year follow-up of 109 patients discharged from the hospital with medical approval, 1955-1956., Am Rev Respir Dis, 90, 61
- W May, 1928, Welche Konsequenzen ergeben sich aus der Dauerstatistik der Heilverfahren bei Offentuberkulösen?, Zeitschr Tuberk, 51, 177
- H Ruge, 1909, Dauererfolge nach 10 Jahren bei Lungetuberkulose im Hochgebirge., Zeitsch Tuberk, 15, 146
- E Saegler, 1934, Beitrag zur Frage der Beziehungen zwischen Tuberkulose und Lebensalter., Zeitschr Tuberk, 71, 285
- E Stadler, 1903, Der Einfluss der Lungetuberkulose of Lebensdauer und Erwerbsfähigkeit und der Werth der Volksheilstättenbehandlung., Deutsch Arch Klin Med, 95, 412
- MG Stephens, 1941, Follow-up of 1041 tuberculous patients., Am Rev Tuberc, 44, 451
- PF Holst, 1906, Untersuchungen über die Lebensdauer der Schwindsüchtigen in Norwegen., Deutsch Arch Klin Med, 88, 325
- H Braeuning, 1920, Tuberkulöse Erkrankungen bei Schwestern infolge von Ansteckung im Dienst und ihre Verhütung., Zeitschr Tuberk, 33, 129
- AD De Besche, 1925, Dødeligheten av Lungentuberkulose i Oslo blandt til Byen indflyttede og der fødte Individer., Norsk Magazin for Laegevidenskaben, 86, 1229
- CRNF Van Joost, 1935, Opmerkingen naar aanleiding van een 200 tal met kunstmatige pneumothorax- en een 50 tal met middenrifsverlamming (phrenicusexairesis) behandelde gevallen van longtuberculose., Geneeskund Tijdschr v Ned Indië, 75, 1223
- B Van Vliet, 1963, Analyse van de sterfte aan longtuberculose te Amsterdam in de jaren 1960 en 1961., Ned Tijdschr Geneesk, 107, 2180
- SP Pamra, 1973, Changes in prevalence and incidence of pulmonary tuberculosis in Delhi in recent years., Ind J Tuberc, 20, 57
- CMF Sinding-Larsen, 1937, On the collapse treatment of pulmonary tuberculosis. A clinical adaption and follow-up examination of the material from Vejlefjord Sanatorium, 1906-1932., Acta Med Scand, 91, 39
- S Magnusson, 1938, Über den Verlauf und die Letalität der Tuberkulose in den verschiedenen Altersperioden., Acta Tuberc Scand, 12, 201
- W Münchbach, 1933, Das Schicksal des lungentuberkulösen Erwachsenen. Ergibnisse der Heilstattenbehandlung von annähernd 10000 Männern und Frauen., Tuberkulose-Bibliothek, 49, 64
- H Braeuning, 1936, Prognose der offenen Tuberkulose, Technik der Prognose-stellung und Rentabilität des Heilverfahrens., Zeitschr Tuberk, 75, 305
- H Braeuning, 1933, Die Prognose der offenen Lungentuberkulose., Tuberkulose-Bibliothek, 52, 40
- H Braeuning, 1930, Über die Letalität, Morbidität und Infektionsdauer der offenen Lungentuberkulose., Zeitschr Tuberk, 59, 109
Cited by
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,170
“fect”): Rapid reduction in the number of replicating bacilli reduces mortality risk [100, 101], and appears to diminish infectiousness, but even optimal therapy on average requires 4–5 weeks to render”
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Walker, T. M., Ip, C. L., Harrell, R. H., Evans, J. T., Kapatai, G., Dedicoat, M. J., Eyre, D. W., Wilson, D. J., Hawkey, P. M., Crook, D. W., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70277-3 · Cited by 918
Dheda, K., Barry, C. E., & Maartens, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00151-8 · Cited by 599
The immunological life cycle of tuberculosis
Ernst, J. D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3259 · Cited by 577
Drain, P. K., Bajema, K. L., Dowdy, D., Dheda, K., Naidoo, K., Schumacher, S. G., Ma, S., Meermeier, E., Lewinsohn, D. M., & Sherman, D. R. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00021-18 · Cited by 565
“regression of disease may also occur (159).”
The global burden of tuberculosis mortality in children: a mathematical modelling study
Dodd, P. J., Yuen, C. M., Sismanidis, C., Seddon, J. A., & Jenkins, H. E. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30289-9 · Cited by 445
Floyd, K., Glaziou, P., Zumla, A., & Raviglione, M. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30057-2 · Cited by 440
Kyu, H. H., Maddison, E. R., Henry, N. J., Ledesma, J. R., Wiens, K. E., Reiner, R., Biehl, M. H., Shields, C., Osgood-Zimmerman, A., Ross, J. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30625-x · Cited by 437
Seifert, M., Catanzaro, D., Catanzaro, A., & Rodwell, T. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119628 · Cited by 326
“Suboptimal treatment and poor adherence to drug therapies contribute to resistance amplification; while lack of detection and subsequent inappropriate treatment increase the risk of direct transmission of drug-resistantMtb [5,8,9].”
BackgroundGlobal Epidemiology of Tuberculosis
Glaziou, P., Sismanidis, C., Floyd, K., & Raviglione, M. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017798 · Cited by 252
“Among HIV-uninfected the risk of death after 10 years has been variously reported between 53% and 86%, with a weighted mean of 70% (Tiemersma et al. 2011), compared with 3% of HIV-uninfected treated tuberculosis patients expected to die because of TB (Straetemans et al.”
The South African tuberculosis care cascade: Estimated losses and methodological challenges
Naidoo, P., Theron, G., Rangaka, M. X., Chihota, V. N., Vaughan, L., Brey, Z. O., & Pillay, Y. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix335 · Cited by 238
MacPherson, P., Houben, R. M., Glynn, J. R., Corbett, E. L., & Kranzer, K. (2014) · Bulletin of the World Health Organization · doi:10.2471/blt.13.124800 · Cited by 230
“Yet pre-treatment loss to follow-up in patients with smear-positive tuberculosis is an important problem for tuberculosis programmes because these patients are highly infectious(44) and experience high morbidity and mortality.(45,46)”
BackgroundKendall, E. A., Fofana, M. O., & Dowdy, D. W. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00458-0 · Cited by 220
Peng, Z., Rojas, A. L. P., Kropff, E., Bahnfleth, W., Buonanno, G., Dancer, S. J., Kurnitski, J., Li, Y., Loomans, M. G. L. C., Marr, L. C., et al. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.1c06531 · Cited by 214
Cholesterol and fatty acids grease the wheels of Mycobacterium tuberculosis pathogenesis
Wilburn, K. M., Fieweger, R. A., & VanderVen, B. C. (2018) · Pathogens and Disease · doi:10.1093/femspd/fty021 · Cited by 195
“Without antibiotic intervention, active TB can be deadly with fatality rates of 53–86 with aweightedmean of 70% in HIV-negative individuals (Tiemersma et al. 2011) and this phase of the disease facilitates the aerosol transmission of the bacteria between humans.”
BackgroundFDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis
Cox, E., & Laessig, K. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314385 · Cited by 187
Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries
Knight, G. M., Griffiths, U. K., Sumner, T., Laurence, Y. V., Gheorghe, A., Vassall, A., Glaziou, P., & White, R. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404386111 · Cited by 190
Global Epidemiology of Tuberculosis
Falzon, D., Floyd, K., Raviglione, M., & Glaziou, P. (2013) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0032-1333467 · Cited by 175
The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal
Kendall, E. A., Shrestha, S., & Dowdy, D. W. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202006-2394pp · Cited by 185
Role of Oxidative Stress in the Pathology and Management of Human Tuberculosis
Shastri, M. D., Shukla, S. D., Chong, W. C., Dua, K., Peterson, G. M., Patel, R. P., Hansbro, P. M., Eri, R., & O’Toole, R. F. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7695364 · Cited by 170
“Without appropriate chemotherapy, untreated smearpositive TB in HIV-negative individuals has a 10-year case fatality between 53% and 86%, with a weighted mean of 70% [18].”
BackgroundDecreasing human body temperature in the United States since the Industrial Revolution
Protsiv, M., Ley, C., Lankester, J., Hastie, T., & Parsonnet, J. (2020) · eLife · doi:10.7554/elife.49555 · Cited by 169
“3% of the population would have been living with active tuberculosis (18).”
BackgroundBiomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial
Scriba, T. J., Fiore-Gartland, A. J., Penn‐Nicholson, A., Mulenga, H., Mbandi, S. K., Borate, B. R., Mendelsohn, S. C., Hadley, K., Hikuam, C., Kaskar, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30914-2 · Cited by 156
Lönnroth, K., Corbett, E. L., Golub, J. E., Godfrey‐Faussett, P., Uplekar, M., Weil, D. E. C., & Raviglione, M. C. (2013) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0797 · Cited by 154
Sharma, A., Hill, A. N., Kurbatova, E. V., der Walt, M. L. V., Kvasnovsky, C., Tupasi, T. E., Caoili, J., Gler, M. T., Volchenkov, G. V., Kazennyy, B. Y., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30247-5 · Cited by 154
Tuberculosis Drug Discovery: Challenges and New Horizons
Fernandes, G., Thompson, A. M., Castagnolo, D., Denny, W. A., & dos Santos, J. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00227 · Cited by 158
Trauer, J. M., Denholm, J. T., & McBryde, E. S. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.05.023 · Cited by 152
“63 over 3 years (Tiemersma et al., 2011) μi TB-specific death rate 0.”
BackgroundInfluentialLedesma, J. R., Ma, J., Zhang, M., Basting, A. V. L., Chu, H. T., Vongpradith, A., Novotney, A., LeGrand, K. E., Xu, Y. Y., Dai, X., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00007-0 · Cited by 146
“To further improve internal consistency of modelling in DisMod, we computed all-age and both-sexes priors of tuberculosis duration using a combination of tuberculosis duration data from a systematic review of studies during the pre-chemotherapy era 25 and the HAQ Index.”
Lieberman, T. D., Wilson, D., Misra, R., Xiong, L. L., Moodley, P., Cohen, T., & Kishony, R. (2016) · Nature Medicine · doi:10.1038/nm.4205 · Cited by 135
β-Lactams against Tuberculosis — New Trick for an Old Dog?
Diacon, A. H., van der Merwe, L., Barnard, M., von Groote-Bidlingmaier, F., Lange, C. G., García‐Basteiro, A. L., Sevene, E., Ballell, L., & Barros-Aguirre, D. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1513236 · Cited by 127
Dheda, K. U. J., Limberis, J. D., Pietersen, E., Phelan, J. E., Esmail, A., Lesosky, M., Fennelly, K. P., Riele, J. T., Mastrapa, B. L., Streicher, E. M., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30433-7 · Cited by 127
Tuberculosis in Adults and Children
Heemskerk, D., Caws, M., Marais, B. J., & Farrar, J. (2015) · SpringerBriefs in public health · doi:10.1007/978-3-319-19132-4 · Cited by 122
“Without treatment, the case fatality for sputum culture positive (HIV negative) patients is estimated to be 70 %, in contrast with sputum culture negative patients for whom it is estimated to be 20 % (Tiemersma et al. 2011).”
BackgroundDowdy, D. W., Basu, S., & Andrews, J. R. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1217oc · Cited by 120
Vaubourgeix, J., Lin, G., Dhar, N., Chenouard, N., Jiang, X., Botella, H., Lupoli, T. J., Mariani, O., Yang, G., Ouerfelli, O., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2014.12.008 · Cited by 121
“When TB does develop but goes untreated, the pathogen takes about 3 years to kill about 70% of its hosts (Tiemersma et al., 2011).”
Latent tuberculosis infection: Opportunities and challenges
Chee, C. B. E., Reves, R. R., Zhang, Y., & Belknap, R. (2018) · Respirology · doi:10.1111/resp.13346 · Cited by 113
Azman, A. S., Golub, J. E., & Dowdy, D. W. (2014) · BMC Medicine · doi:10.1186/preaccept-1380752981388541 · Cited by 107
Sossen, B., Richards, A. S., Heinsohn, T., Frascella, B., Balzarini, F., Oradini‐Alacreu, A., Odone, A., Rogozińska, E., Häcker, B., Cobelens, F. G. J., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00097-8 · Cited by 113
Huynh, G. H., Klein, D. J., Chin, D. P., Wagner, B. G., Eckhoff, P. A., Liu, R., & Wang, L. (2015) · BMC Medicine · doi:10.1186/s12916-015-0341-4 · Cited by 104
“5 years if no treatment is available [65] and is not modeled as variable with clinical presentation.”
BackgroundInfluentialSharifi‐Rad, J., Salehi, B., Stojanović-Radić, Z. Z., Fokou, P. V. T., Sharifi-Rad, M., Mahady, G. B., Sharifi‐Rad, M., Masjedi, M. R., Lawal, T. O., Ayatollahi, S. A., et al. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.07.001 · Cited by 103
“organs, mainly lymph nodes, bones and joints, and genitourinary system 9 (Tiemersma et al., 2011).”
BackgroundRetractedCohen, L. A., & Light, R. W. (2015) · Turkish Thoracic Journal · doi:10.5152/ttd.2014.001 · Cited by 100
Kasaie, P., Andrews, J. R., Kelton, W. D., & Dowdy, D. W. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1846oc · Cited by 89
Assessing tuberculosis control priorities in high-burden settings: a modelling approach
Vesga, J. F., Hallett, T. B., Reid, M. J. A., Sachdeva, K. S., Rao, R., Khaparde, S., Dave, P., Rade, K., Kamene, M., Omesa, E., et al. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30037-3 · Cited by 88
The Nature and Evolution of Genomic Diversity in the Mycobacterium tuberculosis Complex
Brites, D., & Gagneux, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-64371-7_1 · Cited by 91
Assessing Tuberculosis Case Fatality Ratio: A Meta-Analysis
Straetemans, M., Glaziou, P., Bierrenbach, A. L., Sismanidis, C., & van der Werf, M. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020755 · Cited by 102
Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium.
Sharma, S. K., & Mohan, A. (2013) · Europe PMC (PubMed Central) · Cited by 85
Estimating the economic costs of antimicrobial resistance: Model and Results
Taylor, J., Hafner, M., Yerushalmi, E., Smith, R., Bellasio, J., Vardavas, R., Bienkowska-Gibbs, T., & Rubin, J. K. (2014) · RAND Corporation eBooks · doi:10.7249/rr911 · Cited by 114
Clinical standards for the diagnosis, treatment and prevention of TB infection
Migliori, G. B., Wu, S., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., García‐Basteiro, A. L., et al. (2022) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0753 · Cited by 83
Chanda‐Kapata, P., Ntoumi, F., Kapata, N., Lungu, P., Mucheleng’anga, L. A., Chakaya, J. M., Tembo, J. M., Himwaze, C. M., Ansumana, R., Asogun, D., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.033 · Cited by 82
Richards, A. S., Sossen, B., Emery, J. C., Horton, K. C., Heinsohn, T., Frascella, B., Balzarini, F., Oradini‐Alacreu, A., Häcker, B., Odone, A., et al. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00082-7 · Cited by 80
Sharifi‐Rad, J., Salehi, B., Stojanović-Radić, Z. Z., Fokou, P. V. T., Sharifi-Rad, M., Mahady, G. B., Sharifi‐Rad, M., Masjedi, M. R., Lawal, T. O., Ayatollahi, S. A., et al. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107629 · Cited by 77
Kirschner, D. E., Pienaar, E., Marino, S., & Linderman, J. J. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.05.014 · Cited by 77
Aptamer-assisted novel technologies for detecting bacterial pathogens
Alizadeh, N., Memar, M. Y., Moaddab, S. R., & Kafil, H. S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.011 · Cited by 75
Hoog, A. H. V., Onozaki, I., & Lönnroth, K. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-532 · Cited by 73
“It also translates into poor health outcomes in people who get no or too late access to appropriate treatment [2].”
BackgroundHoog, A. H. V., Viney, K., Biermann, O., Yang, B., Leeflang, M., & Langendam, M. W. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010890.pub2 · Cited by 88
Hayward, S. E., Harding, R. M., McShane, H., & Tanner, R. (2018) · F1000Research · doi:10.12688/f1000research.14476.1 · Cited by 73
Potential impact of tuberculosis vaccines in China, South Africa, and India
Harris, R. C., Sumner, T., Knight, G. M., Zhang, H., & White, R. G. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax4607 · Cited by 69
Global estimates of paediatric tuberculosis incidence in 2013–19: a mathematical modelling analysis
Yerramsetti, S. M., Cohen, T., Atun, R. A., & Menzies, N. A. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00462-9 · Cited by 66
“26 For the proportion of time spent in subclinical disease (f), we assumed a mean fraction of 0·25 (0·17–0·33), equivalent to 9 months (6–12), on the basis of research describing a large proportion of individuals who were asymptomatic among prevalent tuberculosis cases.”
Hoog, A. H. V., Langendam, M. W., Mitchell, E. M. H., Cobelens, F. G. J., Sinclair, D., Leeflang, M., & Lönnroth, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010890 · Cited by 66
McCoy, D., Jensen, N., Kranzer, K., Ferrand, R. A., & Korenromp, E. L. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001522 · Cited by 64
Data needs for evidence-based decisions: a tuberculosis modeler's ‘wish list’ [Review article]
Dowdy, D. W., Dye, C., & Cohen, T. (2013) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0573 · Cited by 66
Moon, S. M., Jhun, B. W., Baek, S., Kim, S., Jeon, K., Ko, R., Shin, S. H., Lee, H. J., Kwon, O. J., Huh, H. J., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.03.014 · Cited by 62
Leong, S., Zhao, Y., Joseph, N. M., Hochberg, N. S., Sarkar, S., Pleskunas, J., Hom, D. L., Lakshminarayanan, S., Horsburgh, C. R., Roy, G., et al. (2018) · Tuberculosis · doi:10.1016/j.tube.2018.01.002 · Cited by 77
Diacon, A. H., Barry, C. E., Carlton, A., Chen, R. Y., Davies, M., Jager, V. R. D., Fletcher, K., Koh, G. C. K. W., Kontsevaya, I., Heyckendorf, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02829-7 · Cited by 63
“Without adequate treatment, approximately 70% of patients with active TB will die 3 .”
Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States
Choi, H. W., Miele, K., Dowdy, D. W., & Shah, M. (2013) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0095 · Cited by 60
for the Rede-TB Study group, Mesquita, E. D. D., Gil-Santana, L., Ramalho, D. M. D. P., Tonomura, E., Silva, E., Oliveira, M. M., Andrade, B. B., & Kritski, A. L. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1736-3 · Cited by 60
“tuberculosis infection, a host can develop a wide range of disease manifestations ranging from asymptomatic infection to severe progressive disease [1].”
BackgroundMendelsohn, S. C., Fiore-Gartland, A. J., Penn‐Nicholson, A., Mulenga, H., Mbandi, S. K., Borate, B. R., Hadley, K., Hikuam, C., Musvosvi, M., Bilek, N., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00045-0 · Cited by 68
Para-aminosalicylic acid: the return of an old friend
Donald, P. R., & Diacon, A. H. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00263-7 · Cited by 57
Disrupted human–pathogen co-evolution: a model for disease
Kodaman, N., Sobota, R. S., Mera, R. M., Schneider, B., & Williams, S. M. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00290 · Cited by 57
Ragonnet, R. R., Trauer, J. M., Denholm, J. T., Marais, B. J., & McBryde, E. S. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-016-2171-1 · Cited by 57
Methods used by WHO to estimate the Global burden of TB diseasePreprint
Glaziou, P., Sismanidis, C., Pretorius, C., & Floyd, K. (2016) · arXiv (Cornell University) · doi:10.48550/arxiv.1603.00278 · Cited by 57
Yadav, R. P. H., Nishikiori, N., Satha, P., Eang, M. T., & Lubell, Y. (2014) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.13-0419 · Cited by 58
“in the absence of treatment the average duration to natural cure or death is three years.(9) The proportion of smear-positive and smear-negative cases of bacteriologically positive cases was derived from a recent TB prevalence survey by using solid culture as the gold standard.”
BackgroundKu, C.-C., MacPherson, P., Khundi, M., Soko, R. N., Feasey, H. R. A., Nliwasa, M., Horton, K. C., Corbett, E. L., & Dodd, P. J. (2021) · BMC Medicine · doi:10.1186/s12916-021-02128-9 · Cited by 55
“Similarly, while there are data to suggest a typical duration of around three years for untreated TB disease [9], there is only weak and indirect data to quantify the duration of TB among people living with HIV (PLHIV), which is thought to be much shorter [10].”
BackgroundThomas, B. E., Subbaraman, R., Sellappan, S., Suresh, C., Lavanya, J., Lincy, S., Raja, A. L., Javeed, B., Kokila, S., Arumugam, S., et al. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3039-3 · Cited by 55
“TB patients who are lost to follow-up before starting therapy are infectious and have high mortality rates [5, 6].”
BackgroundInfectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implications
Ryckman, T. S., Dowdy, D. W., & Kendall, E. A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211045119 · Cited by 54
Trajman, A., Durovni, B., Saraceni, V., Menezes, A., Cordeiro‐Santos, M., Cobelens, F. G. J., & van den Hof, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123252 · Cited by 54
“Indeed, data from the pre-chemotherapy era show that there are considerably higher death rates among smear-positive than among smear-negative patients.[13] Because of the stepped-wedge design, each month an increasing proportion of presumptive TB patients were tested with Xpert.”
BackgroundXia, J., Liyun, S., Lifang, Z., & Xu, F. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20140702 · Cited by 53
Setianingrum, F., Rozaliyani, A., Adawıyah, R., Sjam, R., Tugiran, M., Sari, C. Y. I., Nandipinto, F., Ramnath, J., Arifin, A. R., Handayani, D., et al. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-216464 · Cited by 53
“In a review of older studies before the HIV era and before effective therapy for pulmonary TB was available [8], Tiemersma found that even in those with smear positive TB, the spontaneous recovery was 30% (14-47%) and in those with smear negative TB was ~80%.”
BackgroundWolfson, L. J., Walker, A., Hettle, R., Lu, X., Kambili, C., Murungi, A., & Knerer, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120763 · Cited by 52
“The model does not capture the mortality imbalance observed in the placebo-controlled phase II clinical trial in the base case, and instead derives the probability of death from different states described in the literature [30,31].”
BackgroundT-Cell Therapy: Options for Infectious Diseases: Table 1.
Parida, S. K., Poiret, T., Zhenjiang, L., Meng, Q., Heyckendorf, J., Lange, C. G., Ambati, A., Rao, M., Valentini, D., Ferrara, G., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ615 · Cited by 50
“smear-positive pulmonary tuberculosis were able to achieve natural cure by their immune defense mechanisms alone [5].”
Montagna, M. T., Napoli, C., Tafuri, S., Agodi, A., Auxilia, F., Casini, B., Coscia, M. F., D’Errico, M. M., Ferrante, M., Fortunato, A., et al. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-970 · Cited by 49
“Together with HIV/AIDS and malaria, TB is one of the most significant causes of death worldwide, most frequently affecting men in their economically productive age groups [3,4].”
Salje, H., Andrews, J. R., Deo, S., Satyanarayana, S., Sun, A. Y., Pai, M., & Dowdy, D. W. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001674 · Cited by 49
Lolong, D. B., Aryastami, N. K., Kusrini, I., Tobing, K., Tarigan, I. U., Isfandari, S., Senewe, F. P., Raflizar, Pracoyo, N. E., Sitorus, N., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287628 · Cited by 48
Counting the lives saved by DOTS in India: a model-based approach
Mandal, S., Chadha, V. K., Laxminarayan, R., & Arinaminpathy, N. (2017) · BMC Medicine · doi:10.1186/s12916-017-0809-5 · Cited by 48
“Mortality hazards for untreated cases were obtained from studies identified in a systematic review on the natural history of untreated TB [26].”
BackgroundMethodInfluentialDoan, T. N., Fox, G. J., Meehan, M. T., Scott, N., Ragonnet, R. R., Viney, K. A., Trauer, J. M., & McBryde, E. S. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky403 · Cited by 48
Floyd, K., Fitzpatrick, C., Pantoja, A., & Raviglione, M. C. (2013) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70032-9 · Cited by 47
Kendall, E. A., Azman, A. S., Cobelens, F. G. J., & Dowdy, D. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172748 · Cited by 47
Vynnycky, E., Sumner, T., Fielding, K., Lewis, J. J., Cox, A. P., Hayes, R., Corbett, E. L., Churchyard, G., Grant, A. D., & White, R. G. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwu320 · Cited by 46
Gebrecherkos, T., Gelaw, B., & Tessema, B. (2016) · BMC Public Health · doi:10.1186/s12889-016-3761-y · Cited by 46
“The disease spreads in the air when sick people expel the bacteria while talking, coughing, singing, sneezing and spitting [1].”
BackgroundA Bayesian Approach to Understanding Sex Differences in Tuberculosis Disease Burden
Horton, K. C., Sumner, T., Houben, R. M. G. J., Corbett, E. L., & White, R. G. (2018) · American Journal of Epidemiology · doi:10.1093/aje/kwy131 · Cited by 46
“However posterior estimates for untreated-tuberculosis mortality rates among women in these scenarios were over twice those estimated among men, which evidence suggests is unlikely (11).”
BackgroundResultInfluentialTuberculosis and survival in past populations: A paleo-epidemiological appraisal
Blondiaux, J., de Broucker, A., Colard, T., Haque, A., & Naji, S. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.02.002 · Cited by 44
“5 and 1% [39,40].”
Was the First Public Health Campaign Successful?
Anderson, D. M., Charles, K. K., Olivares, C. L. H., & Rees, D. I. (2019) · American Economic Journal Applied Economics · doi:10.1257/app.20170411 · Cited by 61
Bahrainwala, L., Knoblauch, A. M., Andriamiadanarivo, A., Diab, M. M., McKinney, J., Small, P. M., Kahn, J. G., Fair, E., Rakotosamimanana, N., & Lapierre, S. G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235572 · Cited by 44
“Average age of diagnosis (years) 25 NA [34] Age of early death due to TB (years) 28 NA [34]”
BackgroundMethodInfluentialThe global health threat of African urban slums: the example of urban tuberculosis
Oppong, J. R., Mayer, J. D., & Oren, E. (2014) · African Geographical Review · doi:10.1080/19376812.2014.910815 · Cited by 44
Selection of Nucleic Acid Aptamers Specific for Mycobacterium tuberculosis
Mozioğlu, E., Gokmen, O. O., Tamerler, C., KOCAGÖZ, Z. T., & Akgöz, M. (2015) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-015-1913-7 · Cited by 42
Ragonnet, R. R., Trauer, J. M., Geard, N. L., Scott, N., & McBryde, E. S. (2019) · BMC Medicine · doi:10.1186/s12916-019-1452-0 · Cited by 44
García‐Basteiro, A. L., Brew, J., Williams, B. G., Borgdorff, M. W., & Cobelens, F. G. J. (2018) · International Journal of Epidemiology · doi:10.1093/ije/dyy144 · Cited by 42
Self-citationHorton, K. C., Richards, A. S., Emery, J. C., Esmail, H., & Houben, R. M. G. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221186120 · Cited by 46
Burden of Tuberculosis and Challenges Facing Its Eradication in West Africa
Adebisi, Y. A., Agumage, I., Sylvanus, T. D., Nawaila, I. J., Ekwere, W. A., Nasiru, M., Okon, E. E., Ekpenyong, A. M., & Lucero‐Prisno, D. E. (2019) · International Journal of Infection · doi:10.5812/iji.92250 · Cited by 41
“of 10 of those patients with sputum smear-positive TB will die, as oppose about two out of 10 of people with culturepositive but who are smear-negative for TB (10).”
BackgroundDelayed negative effects of prosocial spending on happiness
Falk, A., & Graeber, T. W. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914324117 · Cited by 48
Estimating tuberculosis incidence from primary survey data: a mathematical modeling approach
Pandey, S., Chadha, V. K., Laxminarayan, R., & Arinaminpathy, N. (2017) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.16.0182 · Cited by 40
Metadata
- Authors
- Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- GGD Amsterdam (NL)
- Stellenbosch University (ZA)
- United Arab Emirates University (AE)
- Corresponding author
- Tiemersma, Edine W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-04
- Volume
- 6
- Issue
- 4
- Pages
- e17601
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3070694
- OpenAlex
- W2138041013
- Cited by
- 583
- References
- 136
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 46 · 2023: 48 · 2022: 40 · 2021: 36 · 2020: 38 · 2019: 39 · 2018: 43 · 2017: 42 · 2016: 35 · 2015: 43 · 2014: 39 · 2013: 31 · 2012: 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Keywords
- case fatality, disease duration, HIV-negative patients, smear-positive tuberculosis, smear-negative tuberculosis, culture-positive tuberculosis, tuberculosis prognosis
- MeSH terms
- Humans, Time Factors, Tuberculosis, Pulmonary, Survival Analysis, HIV Seronegativity, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.